Add like
Add dislike
Add to saved papers

Value of various treatments for retroperitoneal fibrosis.

Based on retrospective analysis of 430 cases of retroperitoneal fibrosis, a classification into various etiological groups and an evaluation of the best diagnostic approach and treatment was possible. In patients presenting moderate upper urinary dilation corticosteroids alone proved to be of value in 93% of cases. Azathioprin given in combination with corticosteroids seems to be effective. The surgical 'therapy of choice' was ureterolysis with an effective intraperitoneal transposition. Ureteral restenosis after this procedure (in 22%) occurred mainly when it was not combined with long-term corticosteroid therapy. When the lower half of the ureter is involved we favor ureterolysis, its prevesical section, complete intraperitoneal transposition and a primary psoas-hitch bladder flap.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app